Home › Research › Mild cognitive impairment
Reducing Neuroinflammation and Risk of Mild Cognitive Impairment and Alzheimer’s Disease by Reducing Dietary Lipopolysaccharides, Arachidonic Acid, and Advanced Glycation End Products
Steven Michael Blake, Luciana Baroni, Panida Piboolnurak, Thomas H. Harding, Maile Harding, Catherine Peterson Blake. Journal of dementia and Alzheimer's disease, 2025-08-11
Topic: Brain proteins, microglia and lab models
Triggered by LPS and AGEs in food, inflammatory cytokines can enter the brain and stimulate microglial activation, inflammation, and oxidative damage. AA can elicit neuroinflammation by increasing leukotriene-A4 and prostaglandin-E2 production. Increased levels of neuroinflammation are associated with poorer cognition in AD. A dietary reduction of LPS, AA, and AGEs could slow progression and reduce the risk of cognitive impairment and AD by reducing neuroinflammation through several mechanisms. The avoidance of foods that are highest in LPS, AGEs, and AA (dairy products, pork, poultry, beef, and seafood) and the emphasis on foods lowest in LPS, AGEs, and AA (fruits, vegetables, boiled whole grains, beans, raw nuts, and seeds) can reduce neuroinflammation and risk of cognitive impairment and AD. Reduction of chronic neuroinflammation with dietary changes may represent a novel approach to the treatment of AD and cognitive decline.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Blake, S. M., Baroni, L., Piboolnurak, P., Harding, T. H., Harding, M., & Blake, C. P. (2025). Reducing Neuroinflammation and Risk of Mild Cognitive Impairment and Alzheimer’s Disease by Reducing Dietary Lipopolysaccharides, Arachidonic Acid, and Advanced Glycation End Products. Journal of dementia and Alzheimer's disease. https://doi.org/10.3390/jdad2030027
Vancouver
Blake SM, Baroni L, Piboolnurak P, Harding TH, Harding M, Blake CP. Reducing Neuroinflammation and Risk of Mild Cognitive Impairment and Alzheimer’s Disease by Reducing Dietary Lipopolysaccharides, Arachidonic Acid, and Advanced Glycation End Products. Journal of dementia and Alzheimer's disease. 2025. doi:10.3390/jdad2030027.
BibTeX
@article{blake2025-1cd741dd,
author = {Blake, Steven Michael and Baroni, Luciana and Piboolnurak, Panida and Harding, Thomas H. and Harding, Maile and Blake, Catherine Peterson},
title = {{Reducing Neuroinflammation and Risk of Mild Cognitive Impairment and Alzheimer’s Disease by Reducing Dietary Lipopolysaccharides, Arachidonic Acid, and Advanced Glycation End Products}},
journal = {Journal of dementia and Alzheimer's disease},
year = {2025},
doi = {10.3390/jdad2030027},
url = {https://doi.org/10.3390/jdad2030027}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Triggered by LPS and AGEs in food, inflammatory cytokines can enter the brain and stimulate microglial activation, inflammation, and oxidative damage.
- AA can elicit neuroinflammation by increasing leukotriene-A4 and prostaglandin-E2 production.
- Increased levels of neuroinflammation are associated with poorer cognition in AD.
- A dietary reduction of LPS, AA, and AGEs could slow progression and reduce the risk of cognitive impairment and AD by reducing neuroinflammation through several mechanisms.
- The avoidance of foods that are highest in LPS, AGEs, and AA (dairy products, pork, poultry, beef, and seafood) and the emphasis on foods lowest in LPS, AGEs, and AA (fruits, vegetables, boiled whole grains, beans, raw nuts, and seeds) can reduce neuroinflammation and risk of cognitive impairment and AD.
Why it matters
This narrative review proposes that reducing dietary lipopolysaccharides, arachidonic acid, and advanced glycation end products could lower neuroinflammation and thereby reduce the risk of cognitive impairment and Alzheimer's disease. It presents a hypothesis based on mechanisms, not tested clinical outcomes, so it does not show that dietary changes treat, cure, or prevent Alzheimer's disease.
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of dementia and Alzheimer's disease) |
| Journal's citation record | 0 / 4 | Journal of dementia and Alzheimer's disease: journal h-index 7 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Catherine Peterson Blake holds only 5 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Scientific Society for Vegetarian Nutrition SSNV APS: institution h-index 28 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3390/jdad2030027
- Original source →
- Free full text: Journal of dementia and Alzheimer's disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.